(Q46711629)

English

Increasing the infliximab dose is beneficial in Crohn's disease patients who responded to a lower dose and relapsed

scientific article published on 16 September 2005

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16172549

Increasing the infliximab dose is beneficial in Crohn's disease patients who responded to a lower dose and relapsed (English)

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16172549

Crohn's disease

1 reference

based on heuristic

inferred from title

author name string

Yoram Menachem

1

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16172549

Benjamin Avidan

2

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16172549

Alexandra Lavy

3

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16172549

Alon Lang

4

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16172549

Eytan Bardan

5

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16172549

Herma Fidder

6

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16172549

Simon Bar-Meir

7

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16172549

Yehuda Chowers

8

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16172549

publication date

16 September 2005

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16172549

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16172549

72

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16172549

2-3

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16172549

124-128

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16172549

Inflammatory Bowel Disease

1 reference

https://api.crossref.org/works/10.1159%2F000088367

21 January 2018

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

1 reference

https://api.crossref.org/works/10.1159%2F000088367

21 January 2018

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

1 reference

https://api.crossref.org/works/10.1159%2F000088367

21 January 2018

Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease

1 reference

https://api.crossref.org/works/10.1159%2F000088367

21 January 2018

Identifiers

10.1159/000088367

1 reference

https://api.fatcat.wiki/v0/release/rwkevfleuzgz5gktuxziqbwmiy

30 July 2022

based on heuristic

mapped directly with Wikidata item

release_rwkevfleuzgz5gktuxziqbwmiy

1 reference

https://api.fatcat.wiki/v0/release/rwkevfleuzgz5gktuxziqbwmiy

30 July 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

https://api.fatcat.wiki/v0/release/rwkevfleuzgz5gktuxziqbwmiy

30 July 2022

based on heuristic

mapped directly with Wikidata item

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46711629&oldid=2127718945"